Display options
Cite
Sterns EE, Fletcher WA, Zee B. Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer. Breast Cancer Res Treat. 1992;21(3):193-9doi: 10.1007/BF01975002.
Sterns, E. E., Fletcher, W. A., & Zee, B. (1992). Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer. Breast cancer research and treatment, 21(3), 193-9. https://doi.org/10.1007/BF01975002
Sterns, E E, et al. "Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer." Breast cancer research and treatment vol. 21,3 (1992): 193-9. doi: https://doi.org/10.1007/BF01975002
Sterns EE, Fletcher WA, Zee B. Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer. Breast Cancer Res Treat. 1992;21(3):193-9. doi: 10.1007/BF01975002. PMID: 1515653.
Copy Download .nbib Format: NLM
Share it on

Breast Cancer Res Treat. 1992;21(3):193-9. doi: 10.1007/BF01975002.

Prognostic significance of the immunohistochemical reaction to human milk fat globule antibodies in node-negative and node-positive breast cancer.

Breast cancer research and treatment

E E Sterns, W A Fletcher, B Zee

Affiliations

  1. Department of Surgery, Queen's University, Kingston, Ontario, Canada.

PMID: 1515653 DOI: 10.1007/BF01975002

Abstract

The status of axillary lymph nodes in patients with breast cancer is important prognostically but does not identify all patients who will have long or short survival. To determine if the immunohistochemical reaction of tumor cells to human milk fat globule (HMFG) antibodies will define prognosis more specifically, we examined patients with node-negative disease and patients with more than three positive nodes, the extremes of the prognostic spectrum. In both node-negative and node-positive groups, patients who relapsed were matched by age at diagnosis, tumor size, histologic type, and receptor status, with patients who remained disease-free for a minimum of 48 months. Patients with poor survival had a higher proportion of poorly differentiated cancers. The ability to generate antigens recognized by HMFG antibodies was decreased in patients with recurrent disease, but this was significant only in patients with node-positive tumors. Tumors of patients who remained disease-free were more likely to have a pattern of membrane staining, while cytoplasmic staining was more frequent in those who relapsed. The results suggest that immunohistologic response to HMFG antibodies may assist in identifying cancers with poor prognosis, supplementing the prediction derived from node status.

Similar articles

References

  1. J Exp Pathol. 1986 Summer;2(4):247-60 - PubMed
  2. J Clin Epidemiol. 1988;41(8):727-30 - PubMed
  3. J Clin Pathol. 1979 Jan;32(1):35-9 - PubMed
  4. Cancer. 1986 Apr 1;57(7):1415-20 - PubMed
  5. Surgery. 1991 Oct;110(4):617-22 - PubMed
  6. Cancer. 1984 Feb 1;53(3 Suppl):712-23 - PubMed
  7. J Histochem Cytochem. 1988 Mar;36(3):317-22 - PubMed
  8. Cancer. 1990 Jul 15;66(2):331-40 - PubMed
  9. N Engl J Med. 1988 Dec 29;319(26):1681-92 - PubMed
  10. Cancer Res. 1989 Apr 15;49(8):2087-90 - PubMed
  11. Surg Gynecol Obstet. 1989 Jul;169(1):81-98 - PubMed
  12. Cancer. 1986 Dec 15;58(12):2662-70 - PubMed
  13. Br J Cancer. 1957 Sep;11(3):359-77 - PubMed
  14. Br J Cancer. 1985 Feb;51(2):179-86 - PubMed
  15. Ann Surg. 1981 Jul;194(1):1-3 - PubMed

Substances

MeSH terms

Publication Types

LinkOut - more resources